Price T Rowe Associates Inc. MD Buys 2,425 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Price T Rowe Associates Inc. MD grew its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 18.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 15,824 shares of the biopharmaceutical company’s stock after acquiring an additional 2,425 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Vanda Pharmaceuticals were worth $66,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. GSA Capital Partners LLP lifted its holdings in shares of Vanda Pharmaceuticals by 39.8% during the fourth quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock valued at $2,396,000 after purchasing an additional 161,737 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of Vanda Pharmaceuticals by 39.6% during the first quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock valued at $2,132,000 after purchasing an additional 147,066 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Vanda Pharmaceuticals during the first quarter valued at $1,158,000. Acadian Asset Management LLC lifted its holdings in shares of Vanda Pharmaceuticals by 4.7% during the first quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock valued at $9,740,000 after purchasing an additional 107,203 shares in the last quarter. Finally, Raymond James & Associates bought a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $42,000. 88.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. StockNews.com assumed coverage on Vanda Pharmaceuticals in a report on Tuesday, August 13th. They set a “hold” rating on the stock. Cantor Fitzgerald upped their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

Vanda Pharmaceuticals stock opened at $5.20 on Monday. The stock has a market cap of $303.11 million, a PE ratio of -65.00 and a beta of 0.75. Vanda Pharmaceuticals Inc. has a one year low of $3.30 and a one year high of $6.75. The stock has a fifty day moving average of $5.76 and a 200 day moving average of $4.96.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.